Rama Suresh

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

Timothy M. Nywening, Andrea Wang‐Gillam, Dominic E. Sanford et al. · The Lancet Oncology · 2016 · 778 citations · Full text

Medicine, Oncology, Pharmacology +16

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

Shunqiang Li, Dong Shen, Jieya Shao et al. · Cell Reports · 2013 · 625 citations · Full text

Medicine, Genetics, Oncology +14

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

X. Cynthia, Feng Gao, Jingqin Luo et al. · Clinical Cancer Research · 2017 · 376 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Multi-Institutional Experience with FOLFIRINOX in Pancreatic Adenocarcinoma

Parvin F. Peddi, Sam Joseph Lubner, Robert R. McWilliams et al. · PubMed · 2012 · 112 citations · Full text

Medicine, Oncology, Pharmacology +17

Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

Andrea Wang‐Gillam, Kian‐Huat Lim, Robert R. McWilliams et al. · Clinical Cancer Research · 2022 · 106 citations · Full text

Medicine, Oncology, Pharmacology +17